1. Home
  2. JANX vs SID Comparison

JANX vs SID Comparison

Compare JANX & SID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

N/A

Current Price

$10.13

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Companhia Siderurgica Nacional S.A.

SID

Companhia Siderurgica Nacional S.A.

N/A

Current Price

$0.51

Market Cap

833.8M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
JANX
SID
Founded
2017
1941
Country
United States
Brazil
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Steel/Iron Ore
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
833.8M
IPO Year
2021
2002

Fundamental Metrics

Financial Performance
Metric
JANX
SID
Price
$10.13
$0.51
Analyst Decision
Buy
Sell
Analyst Count
18
4
Target Price
★ $33.14
$1.17
AVG Volume (30 Days)
946.4K
★ 10.8M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $10,000,000.00
N/A
Revenue This Year
$174.21
N/A
Revenue Next Year
N/A
$1.87
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$10.16
$0.55
52 Week High
$35.34
$2.20

Technical Indicators

Market Signals
Indicator
JANX
SID
Relative Strength Index (RSI) 25.34 24.87
Support Level N/A N/A
Resistance Level $14.47 $1.34
Average True Range (ATR) 1.16 0.07
MACD -0.48 -0.02
Stochastic Oscillator 0.33 1.23

Price Performance

Historical Comparison
JANX
SID

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About SID Companhia Siderurgica Nacional S.A.

Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations port concessions and fleets of road transport vehicles. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.

Share on Social Networks: